基蛋生物收盘下跌2.11%，滚动市盈率22.18倍，总市值44.78亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of the company,基蛋生物, within the medical device industry [1][2] - As of August 22, the company's stock closed at 8.83 yuan, down 2.11%, with a rolling PE ratio of 22.18 times and a total market capitalization of 4.478 billion yuan [1] - The average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, placing the company at the 47th position in the industry ranking [1][2] Group 2 - As of March 31, 2025, the number of shareholders for the company is 26,747, a decrease of 451 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, being a key supplier in the POCT field [1] - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross margin of 77.15% [1]